1. Home
  2. EDSA vs JAGX Comparison

EDSA vs JAGX Comparison

Compare EDSA & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • JAGX
  • Stock Information
  • Founded
  • EDSA 2015
  • JAGX 2013
  • Country
  • EDSA Canada
  • JAGX United States
  • Employees
  • EDSA N/A
  • JAGX N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EDSA Health Care
  • JAGX Health Care
  • Exchange
  • EDSA Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • EDSA 6.2M
  • JAGX 7.4M
  • IPO Year
  • EDSA N/A
  • JAGX N/A
  • Fundamental
  • Price
  • EDSA $2.03
  • JAGX $5.88
  • Analyst Decision
  • EDSA Strong Buy
  • JAGX
  • Analyst Count
  • EDSA 1
  • JAGX 0
  • Target Price
  • EDSA $21.00
  • JAGX N/A
  • AVG Volume (30 Days)
  • EDSA 14.5K
  • JAGX 247.5K
  • Earning Date
  • EDSA 05-14-2025
  • JAGX 05-15-2025
  • Dividend Yield
  • EDSA N/A
  • JAGX N/A
  • EPS Growth
  • EDSA N/A
  • JAGX N/A
  • EPS
  • EDSA N/A
  • JAGX N/A
  • Revenue
  • EDSA N/A
  • JAGX $11,689,000.00
  • Revenue This Year
  • EDSA N/A
  • JAGX $22.41
  • Revenue Next Year
  • EDSA N/A
  • JAGX $30.00
  • P/E Ratio
  • EDSA N/A
  • JAGX N/A
  • Revenue Growth
  • EDSA N/A
  • JAGX 19.75
  • 52 Week Low
  • EDSA $1.55
  • JAGX $4.02
  • 52 Week High
  • EDSA $5.59
  • JAGX $502.50
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 36.85
  • JAGX 37.09
  • Support Level
  • EDSA $1.99
  • JAGX $5.30
  • Resistance Level
  • EDSA $2.14
  • JAGX $13.20
  • Average True Range (ATR)
  • EDSA 0.11
  • JAGX 1.49
  • MACD
  • EDSA -0.03
  • JAGX -0.57
  • Stochastic Oscillator
  • EDSA 21.28
  • JAGX 7.30

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: